Journal
PHARMACOGENOMICS JOURNAL
Volume 9, Issue 3, Pages 208-217Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/tpj.2009.4
Keywords
CYP1A2; drug-metabolizing enzyme; gene expression; allele-specific expression; epigenetics; DNA methylation
Categories
Funding
- Swedish Research Council for Medicine
- Swedish Research Council for Science and Technology
- Torsten and Ragnar Soderbergs Stiftelser
Ask authors/readers for more resources
The basis for interindividual variation in the CYP1A2 gene expression is not fully understood and the known genetic polymorphisms in the gene provide no explanation. We investigated whether the CYP1A2 gene expression is regulated by DNA methylation and displays allele-specific expression (ASE) using 65 human livers. Forty-eight percent of the livers displayed ASE not associated to the CYP1A2 mRNA levels. The extent of DNA methylation of a CpG island including 17 CpG sites, close to the translation start site, inversely correlated with hepatic CYP1A2 mRNA levels (P = 0.018). The methylation of two separate core CpG sites was strongly associated with the CYP1A2 mRNA levels (P = 0.005) and ASE phenotype (P = 0.01), respectively. The CYP1A2 expression in hepatoma B16A2 cells was strongly induced by treatment with 5-aza-2'-deoxycytidine. In conclusion, the CYP1A2 gene expression is influenced by the extent of DNA methylation and displays ASE, mechanisms contributing to the large interindividual differences in CYP1A2 gene expression. The Pharmacogenomics Journal (2009) 9, 208-217; doi:10.1038/tpj.2009.4; published online 10 March 2009
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available